CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.
Leukemia
; 32(11): 2307-2315, 2018 11.
Article
em En
| MEDLINE
| ID: mdl-30315238
ABSTRACT
Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrated remarkable efficacy for the treatment of B-cell malignancies. The development of CAR T-cells against T-cell malignancies appears more challenging due to the similarities between the therapeutic, normal and malignant T-cells. The obstacles include CAR T-cell fratricide, T-cell aplasia, and contamination of CAR T-cell products with malignant T-cells. Here, we review these challenges and propose solutions to overcome these limitations.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T
/
Linfoma de Células B
/
Receptores de Antígenos Quiméricos
/
Neoplasias
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
França